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https://doi.org/10.1016/j.stemcr.2018.08.007SUMMARYMast cells are tissue-resident immune cells. Their overgrowth/overactivation results in a range of common distressing, sometimes life-
threatening disorders, including asthma, psoriasis, anaphylaxis, and mastocytosis. Currently, drug discovery is hampered by use of can-
cer-derived mast cell lines or primary cells. Cell lines provide low numbers of mature mast cells and are not representative of in vivomast
cells. Mast cell generation from blood/bonemarrow gives poor reproducibility, requiring 8–12 weeks of culture. Here we report a method
for the rapid/robust production ofmast cells frompluripotent stem cells (PSCs). An advantageousGata2Venus reporter enrichesmast cells
and progenitors as they differentiate from PSCs. Highly proliferativemousemast cells and progenitors emerge after 2 weeks. Thismethod
is applicable for rapid human mast cell generation, and could enable the production of sufficient numbers of physiologically relevant
human mast cells from patient induced PSCs for the study of mast cell-associated disorders and drug discovery.INTRODUCTION
As tissue-resident immune cells,mast cells are the key effec-
tors in common immunological disorders affecting world-
wide populations. These include allergies, asthma, eosino-
philic esophagitis, celiac disease, mastocytosis, atopic
dermatitis, and psoriasis. A characteristic feature of mast
cells is the large cytoplasmic granules containing proteases
that are released upon activation, for example during an
allergic reaction. Activation of mast cells occurs via a num-
ber of different agents: immunoglobulin E (IgE), damage-/
pathogen-induced molecules, and complement compo-
nents (reviewed in Rudich et al., 2012). These cells act
viscerally in the CNS and also at the blood-brain barrier,
causing a wide variety of symptoms in complex diseases
that are difficult and often impossible to diagnose. More
recently they are suspected to affect pain and neuroinflam-
mation in endometriosis (Theoharides et al., 2015). Strate-
gies to limit the damaging effects of mast calls are needed.
Dependent upon their tissue of residence, mast cells
differentially produce a variety of proteases, such as
chymase, tryptase and/or histamine (Schwartz and Austen,
1980). Murine connective tissue-type mast cells express
heparin, high concentrations of histamine, tryptases
(mMCP-6 and -7), chymases (mMCP-4 and -5), and
carboxypeptidase A (CPA), whereas mucosal mast cells
lack heparin and express low levels of histamine and chy-
mases (mMCP-1 and -2) (Galli et al., 2011). Mast cells in
the human also differentially express chymase and tryp-
tase, with classical mast cells being tryptase+chymase+
and tryptase+chymase (Bischoff, 2007; Weller et al.,Stem Cell Repo
This is an open access article under the C2007). Recently a new mast cell type (tryptasechymase+)
has been found in endometrial tissue (De Leo et al.,
2017). The fact that these endometrial mast cells express
steroid receptors suggests that mast cell function is altered
by the local microenvironment.
Treatment options focusing on the modulation of mast
cell activity are limited, and the development of new ther-
apies is hampered by challenges in generating sufficient
phenotypically mature mast cells for biomedical discovery
and drug screening (Holm et al., 2006; Saito et al., 2006;
Shimizu et al., 2002; Wang et al., 2006). Direct isolation
of mast cells is inefficient (Dahlin et al., 2016) and results
in an altered phenotype. Moreover, the ex vivo generation
of mast cells from human blood precursors involves
extended culture periods, expensive reagents, and low/
variable yields (Kirshenbaum and Metcalfe, 2006). Plurip-
otent stem cells (PSCs) offer an alternative source for
obtaining mature mast cells for research. However, the
published protocols are time consuming, as mast cells
emerge after 4–8 weeks of mouse PSC culture (Moller
et al., 2007; Tsai et al., 2002; Westerberg et al., 2012; Ya-
maguchi et al., 2013) and only after 5–10 weeks of human
PSC culture (Kovarova et al., 2010) (Table 1). Further pro-
longed culture is needed to increase mast cell yield, as the
cells are cumulatively harvested and do not enable
prompt production of large numbers of mast cells. The
lack of an efficient protocol to rapidly obtain large
numbers of mature mast cells for research has restricted
drug development and progress in understanding and
treating mast cell-related disorders; thus, new approaches
for mast cell production are needed.rts j Vol. 11 j 1009–1020 j October 9, 2018 j ª 2018 The Authors. 1009
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1. Duration of Cultures Used for Mast Cell Generation
from Different Cell/Tissue Sources
Source Culture Time Reference
hPB 8–12 weeks Kirshenbaum and Metcalfe, 2006;
Saito et al., 2006; Wang et al.,
2006
hCB 12 weeks Holm et al., 2006
hBM 12 weeks Shimizu et al., 2002
mESC 4–8 weeks Moller et al., 2007; Tsai et al.,
2002; Westerberg et al., 2012
miPSC 4 weeks Yamaguchi et al., 2013
hESC 10 weeks Kovarova et al., 2010
hiPSC 5 weeks Igarashi et al., 2018
G2V mESC 14–21 days this study
G2V hESC/iPSC 12–16 days this study
Duration (weeks/days) of cultures for human (h) mast cell generation from
progenitors isolated from primary tissue sources such as peripheral blood
(hPB), cord blood (hCB), and bone marrow (hBM); from wild-type and
Gata2Venus (G2V) reporter mouse embryonic stem cells (mESC); and human
ESCs (hESC) and induced pluripotent stem cells (iPSC). References for each
of the studies are indicated.Here we report an innovative method for the rapid and
abundant production of mouse mast cells that relies on
Gata2Venus (G2V) reporter PSCs (Kaimakis et al., 2016),
and show that it is also applicable for the generation of hu-
man mast cells. The rationale for this reporter is that the
Gata2 transcription factor is highly expressed in mast cells
(Jippo et al., 1996). Its expression is essential for mast cell
precursor development and expansion (Tsai and Orkin,
1997) and the function of mature mast cells (Masuda
et al., 2007).Gata2-deficientmouse and human embryonic
stem cells (ESCs) show abrogated hematopoietic differenti-
ation (Huang et al., 2015; Tsai et al., 1994). Previously, we
showed in mouse G2V ESCs and G2V embryos that Venus
reporter expression mirrors that of Gata2without affecting
Gata2 expression levels (Kaimakis et al., 2016; Kauts et al.,
2016, 2018). Gata2 is expressed in all hematopoietic stem
cells (HSCs) and most progenitors (HPCs) in vivo (Kaimakis
et al., 2016).With the exception ofmast cells and basophils
(Sasaki et al., 2016), Gata2 expression is downregulated
when immatureHPCs differentiate, thusmaking it a poten-
tially specific reporter for the mast/basophilic cell lineage
(Akashi et al., 2000; Guo et al., 2013; Miyamoto et al.,
2002; Orlic et al., 1995). We demonstrate here the rapid
and efficient production of mast cells from mouse G2V
reporter ESCs, and show that this reporter-based system is
applicable for the rapid production of mast cells from hu-
man G2V ESCs and induced PSCs (iPSCs).1010 Stem Cell Reports j Vol. 11 j 1009–1020 j October 9, 2018RESULTS
Abundant Production of Phenotypic Mast Cells from
Mouse ESCs
Our recent data show that all functional HPCs generated in
mouse ESC (mESC) differentiation cultures are Gata2 ex-
pressing, with a peak of HPC activity at day 10 of ESC cul-
ture (Kauts et al., 2016, 2018). With an initial aim to test
whether further hematopoietic induction would lead to
the development of transplantable HSC/HPC, a three-stage
culture was established. In stage 1, G2VmESCs were differ-
entiated to embryoid bodies (EBs) for 10 days (Figure 1A).
Venus+ (V+) cells (1.6% of viable EB-derived cells; Figure 1B)
were harvested and in stage 2, cultured on a monolayer of
OP9 stromal cells for 4 days. The average number of V+ cells
obtained from day-10 EBs (33 104 starting ESCs) was 1.5 ±
0.3 3 104 (Table 2). Round non-adherent hematopoietic
cells appeared in the OP9 co-culture after 2–3 days (Fig-
ure 1C) and after 4 days, 37% ± 6.8% of the cells expressed
high levels of Venus (Figure 1D). Only V+ cells specifically
co-expressed the pan-leukocyte marker CD45, and 99% ±
0.6% of V+CD45+ cells were positive for the CKIT
(CD117) HSC/HPC marker (Figure 1E). In the stage 3 cul-
ture, day-14 V+ cells were seeded in methylcellulose and
progenitor numbers analyzed at days 18–21.
To assess the V+CD45+ cell population after stage 2, we
analyzed mature blood lineage (Lin) marker expression:
MAC1 (macrophage), GR1 (granulocyte/monocyte),
CD19 (lymphocyte), and TER119 (erythroid) (Figure 1F).
None of these markers were expressed on day-14
V+CD45+ cells. As phenotypic HSCs/HPCs are Lin and ex-
press GATA2 (Kaimakis et al., 2016; Kauts et al., 2016,
2018), CKIT (Sanchez et al., 1996) and CD45 (McKinney-
Freeman et al., 2009; North et al., 2002), we examined
whether functional HSC/HPC-like cells were generated in
the differentiation culture by the in vivo colony forming
unit-spleen assay (CFU-S). At day 8 post transplantation
of day-14 V+CD45+Lin cells into lethally irradiated adult
mice (two injected with 1,200 and one injected with
20,000 cells), no donor-derived CFU-S activity was found
(Figure 1G).
Since mast cells are also known to express GATA2, CKIT,
and CD45 (Dahlin et al., 2016; Jippo et al., 1996; Sasaki
et al., 2016), we examined differentiated ESCs for expres-
sion of the high-affinity IgE receptor 1a (FC 3RIa), a mast
cell marker. At day 10, 35%–36% of V+ cells were CKIT+
(Figure 1H, upper panels); 37% of these V+CKIT+ cells
were CD45+ and only 2.5% of V+CKIT+ cells were FC 3RIa+.
In contrast, 83% ± 4.4% of V+CD45+CKIT+ cells after day
14 were FC 3RIa+ (Figure 1H, lower right panel). 5.7% ±
3.5% of day-14 VCD45 cells showed some low-level
CKIT expression, but none of these cells were FC 3RIa+ (Fig-
ure 1H, lower left panel). These data suggest that at day 14,
most V+CKIT+CD45+ cells are mast cells/progenitors and
that at day 10 most V+CKIT+CD45+/ cells are phenotypic
HPCs. As it is thought that mast and basophilic cells ex-
press higher levels of GATA2 than HPCs (Kaimakis et al.,
2016), the mean fluorescent intensity (MFI) of VENUS
expression was examined (Figure 1I). Compared with
day-10 differentiated cells, the day-14 cells exhibited a
3.5-fold higher MFI. To further verify the mast cell pheno-
type of the ESC-derived V+ cells, we examined the expres-
sion of a basophilic marker, CD49B, on these cells by fluo-
rescence-activated cell sorting (FACS) analysis (Figure S1).
Basophils are known to be CKIT, FC 3RIa+, and CD49B+.
Compared with cultured mouse bone marrow CD45+ cells
(Figure S1C), which show both CD49B mast cells and
CD49B+ basophils, only a negligible percentage of ESC-
derived cells (Figure S1A) and cultured peritoneal mast cells
(Figure S1B) were CD49B+, thus demonstrating that the
great majority of ESC-derived cells have acquired a mast
cell and/or mast cell progenitor phenotype after 14 days.
Development and Expansion of G2VMast Cells
To analyze the growth capacity of the V+mast cells/progen-
itors, we plated single V+ cells harvested fromday-4OP9 co-
cultures in methylcellulose stage 3 culture. After 3–4 days,
macroscopic homogeneous colonies appeared (Figure 2A),
indicating a large degree of rapid expansion. In total, a
starting culture of 3 3 104 ESCs can yield up to 3.8 3 106
mature mast cells (average 1.6 ± 0.5 3 106) (Table 2). This
is up to 8-fold more cells generated in 21 days than previ-
ously reported after 5 or more weeks of mESC culture
(0.5 3 106 cells) (Westerberg et al., 2012), and 2-fold
more mast cells 1 week earlier than from mouse iPSCs
(Yamaguchi et al., 2013).
Mast cell identity was confirmed by toluidine blue stain-
ing (cytoplasmic granule-specific). One hundred percent of
the cells after stage 3 culture were toluidine blue positive,
but to varying degrees. In contrast to the adult connective
tissue-typemast cells in the skin that are dark-staining (due
to heparin) andmucosal-typemast cells in the gut and lung
that are weak-staining (Bischoff, 2007; Weller et al., 2007),
the staining differences in the ESC-derived mast cells
are likely to represent different stages of differentiation
(Figure 2B).
G2VMast Cells Express Proteases and Receptors
Characteristic of Mature Mast Cells
Mature mast cells produce high levels of inflammatory me-
diators that are stored in large cytoplasmic secretory gran-
ules (Schwartz and Austen, 1980). The expression of genes
encoding the inflammatory mediators of connective tissue
mast cells (mMCP-5, mMCP-6, and CPA-3) and of mucosal
mast cells (mMCP-1) was examined in undifferentiated
mESCs, V+ stage 1 cells, and stage 3 expanded mast cells,and after serial clonal replating (rpMC) (Figure 2C).
CPA-3, mMCP-1, mMCP-5, and mMCP-6 were highly ex-
pressed in all mast cell samples before and after serial re-
plating, with only low/negligible expression in some
ESCs or stage 1 samples. Mast cell receptor genes cKit and
Fc 3R1a were expressed before and after replating in all
mast cell samples, with some low cKit expression in ESCs.
High levels of Gata2 were detected in stage 1 cells and in
stage 3 mast cells before and after replating. The fact that
the clonal expansion capacity, cellular morphology (Fig-
ure 2D), and gene expression profile (Figure 2C) of the
mast cells were retained after serial replating suggests that
these cultures maintain self-renewing cells, most likely
mast cell progenitors (MCp).
Gene expression levels of the chemical mediators and
mast cell receptors in G2V ESC-derived mast cells was
compared with expression in control murine ear tissue
(the ear is known to contain a high frequency ofmast cells).
cKit, Fc 3R1a, and Fc 3R1g were respectively expressed 560 ±
39, 2,802 ± 1,690 and 644 ± 66 times more than the con-
trol, and mMCP-5, mMCP-6, and CPA-3 were expressed at
1,727 ± 402, 570 ± 58, and 3,818 ± 621 times higher than
in the control (Figure 2E). Moreover, G2V ESC-derived
mast cells (CD45+CKIT+FC 3R1a+) and control peritoneal
mast cells (CD45+CKIT+FC 3R1a+) did not express the baso-
philic protease gene mMcpt8, whereas cultured bone
marrow CD45+CKITFC 3R1a+ cells expressed high levels
ofmMcpt8 (Figure S1D). As expected, cKitmRNAwas found
in both ESC and peritoneal mast cells but not in basophils.
These gene expression data confirm the highly enriched
and rapid production of mast cells fromG2V ESCs and sug-
gest that these mast cells are functional.
G2VMast Cells Are Activated upon Extracellular
Stimulation
Allergic responses in vivo result from the activation and
degranulation of mast cells. To test whether G2Vmast cells
are functionally responsive, we treated cells with com-
pound 48/80 (c48/80) (Lagunoff and Rickard, 1983), a
known secretagog of mast cells. After 60 min of c48/80
stimulus (5 mg/mL) a significantly 1.6-fold higher tryptase
level was found in the cellmedia as comparedwith the con-
trol unstimulated sample (Figure 2F). An FC 3R1a-mediated
degranulation assay was also performed on G2V-mESC-
derived mast cells and control mouse peritoneal mast cells
(Figure 2G). In the absence of activation, some leakiness (as
measured by percentage of b-hexosaminidase release)
was observed. However, when IgE-sensitized G2V-mESC-
derived mast cells were stimulated by adding antigen to
the ESC-derived mast cells, a significant 2-fold increase in
degranulation occurred that was in accordance with the
increased degranulation levels (also significant) seen in
the peritoneal mast cell controls. Together, these dataStem Cell Reports j Vol. 11 j 1009–1020 j October 9, 2018 1011
Figure 1. G2V mESC Differentiation and VENUS Enrichment Facilitates Rapid and Robust Mast Cell Generation
(A) Three-stage differentiation protocol for mast cell production. Stage 1 is hematopoietic commitment in 10-day embryoid body (EB)
culture. At day 10, GATA2VENUS+ (V+) cells are sorted and plated onto OP9 cells in stage 2, where mast cell commitment is induced to yield
(legend continued on next page)
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demonstrate that the G2V ESC-derived mast cells can be
activated and respond to common mast cell activating
extracellular stimuli, triggering the release of chemical
mediators.
Human G2V Reporter PSC Differentiation as an
Innovative Approach for Rapid Human Mast Cell
Production
In studies related to the involvement of mast cell in endo-
metriosis, we generated mast cells from human CD34+ pe-
ripheral blood cells by a widely used method (Kirshen-
baum and Metcalfe, 2006). Density gradient-enriched
CD34+ progenitor cells were cultured in serum-free me-
dium with growth factors for 8 weeks (Figure S2A). At 2
and 3 weeks, only a few low toluidine blue-stained cells
were detected, whereas intensely blue cells indicative of
mast cells predominated in 8-week cultures. Further char-
acterization showed upregulated expression of human
mast cell protease/receptor genes (Figure S2B). Little to
no expression was found at week 1, but statistically signif-
icant 20-fold to 70-fold increases of TPSAB1 (tryptase a/b
isoforms) and CMA1 (chymase1) expression were found
at 4 and 8 weeks. PAR2 (protease activated receptor2)
and HR1 (histamine receptor1) expression showed signifi-
cant increases only at week 8. These results are consistent
with the presence of mast cells at week 8 of PBC CD34+
culture. Also, a human mast cell line, HMC-1, showed
significantly lower expression of the mast cell genes
TPSAB1, CMA1, PAR2, and HR1 compared with 8-week
differentiated CD34+ PBCs (Figure S2C), thus demon-
strating that HMC1 is not a relevant alternative to over-
come the challenge of long duration of mature human
mast cell production, and highlighting the need for devel-
oping novel culture methods.highly proliferating mast cells that appear after 3–4 days. At day 14
expansion in stage 3.
(B) FACS dot plot of cells from day 10 G2V mouse EBs showing gating
(C) Visible-light image of a 4-day OP9 co-culture in which round refrac
Scale bar, 100 mm.
(D) FACS analysis of cells harvested after 4 days of OP9 co-culture. 3
(E) 99% ± 0.6% of V+CD45+ cells shown in (D) are CKIT+ hematopoiet
(F) FACS dot plots showing lack of B-lymphoid (CD19), macrophag
lineage-positive cells in V+CD45+ population after 4 days of OP9 co-c
(G) DNA PCR data of six representative spleen colonies from CFU-S as
derived cells. Sorted cells injected into irradiated mice formed a few s
alleles shows that the CFU-S did not originate from the ESC-derived cell
ESC DNA.
(H) FACS analysis of (top) day-10 V+ cells for CKIT, CD45, and FC 3R1a e
mature mast cells. FACS analysis of day-14 VCD45 cells (bottom le
stage 2. Mean ± SEM, n = 6.
(I) FACS histogram of VENUS expression intensity of day-10 (black)
VENUS mean fluorescence intensity (MFI) at days 10 (black) and 14 (re
cells. Mean ± SEM, **p < 0.01, n = 3.Our ability to rapidly producemast cells from theG2V re-
portermESCs, togetherwith the known conservation inhe-
matopoietic development and Gata2 expression/function
in mouse and man, suggested that the GATA2 reporter
could be applied to human PSCs (hPSCs) for the production
of human mast cells. Thus, we established GATA2Venus re-
porter human ESCs (hESCs) and iPSCs in a strategy similar
to that used with G2V mESCs. A 2A-Venus sequence was
introduced into the human GATA2 (hGATA2) 30 UTR by
the CRISPR/Cas9 method (Figure S3A). One clone of
GATA2Venus reporter human ESCs (G2V-hESC) and two in-
dependent clones of iPSCs (G2V-hiPCS1;G2V-hiPCS2)were
characterized (Figure S3B) for GATA2 expression and he-
matopoietic differentiation. V+ sorted cells from day-6 dif-
ferentiation cultures of all three cell lines expressed high
levels of GATA2 compared with V cells (Figure S3C). At
day 12, flow cytometry showed that 38%–70% of cells
were V+ and that 6%–18% of V+ cells expressed the CD41
hematopoietic marker (Figure S3D). Moreover, most HPCs
(>90%) were enriched in the V+ fraction of differentiated
G2V hESCs and hiPSCs (Figure S2E) as shown by in vitro
CFU-cell assays. All erythroid and myeloid hematopoietic
colony typeswere present. These results are in linewith pre-
vious analyses of mESCs (Kauts et al., 2016, 2018) and
hESCs/hiPSCs (Huang et al., 2015), and show that GATA2
is an efficient reporter for human HPCs.
To test whether our rapid Gata2 reporter-based mouse
mast cell generation method is also applicable for mast
cell generation from hPSCs, we applied the staged differen-
tiation culture protocol to the three independent cell lines,
G2V-hiPSC-1,G2V-hiPSC-2, andG2V-hESC. Following 7, 8,
and 11 days of differentiation, respectively, cells were
sorted based on Venus expression and co-cultured with
OP9 cells for 4–5 days. Of the 3.4 3 104, 8.9 3 104, and, V+ mast cells/progenitors are isolated for analysis/further clonal
used for sorting V+ cells (1.6%) after stage 1.
tive mast cells are observed overlaying the adherent large OP9 cells.
7% ± 6.8% of cells are V+ and CD45+ (red gated area).
ic cells. Mean ± SEM, number of independent experiments (n) = 6.
e (MAC1), granulocyte/basophil (GR1), and erythrocyte (TER119)
ulture.
say testing the in vivo repopulation potential of V+CD45+Lin ESC-
mall spleen colonies at 9 days post injection. PCR for G2V and Gata2
s. Negative control is wild-type (wt) ESC DNA. Positive control is G2V
xpression shows commitment to hematopoietic progenitors but not
ft) and V+CD45+ cells (bottom right; 83% mast cells) isolated after
and day-14 (red) differentiated cells. Bar graph quantification of
d) showing significantly higher Venus protein levels in day-14 mast
Stem Cell Reports j Vol. 11 j 1009–1020 j October 9, 2018 1013
Table 2. Mast Cell Generation and Frequency in the G2V mESC
Multistep Cultures
Experiment
Stage 1: V+
Cells from
3 3 104 ESCs
Stage 2: MC/MCp
from 3 3 104
ESCs
Stage 3: MC
Yield from
3 3 104 ESCs
1 11,504 14,923 1,242,200
2 30,000 2,781 937,000
3 7,541 2,623 3,834,375
4 9,653 1,990 570,313
5 20,087 6,421 1,156,250
6 13,764 6,875 1,906,250
Mean 15,425 5,936 1,607,731
±SEM ±3,405 ±1,986 ±479,952
Number of VENUS+ cells after stage 1 at day 10, VENUS+ mast cells/mast cell
progenitors (MC/MCp) after OP9 co-culture stage 2 at day 14, and total mast
cell yield after stage 3 methylcellulose expansion at days 18–21 from 3 3
104 input Gata2Venus mouse ESCs; six independent experiments, and
mean ± SEM.3.4 3 104 viable cells harvested from the G2V-hiPSC-1,
G2V-hiPSC-2, and G2V-hESC OP9 co-cultures, 4.3%,
5.2%, and 3.0%, respectively were Venus expressing,
yielding 278, 241, and 906 CKIT+FC 3RIa+ phenotypic
mast cells (7.8%, 5.5%, and 19%, respectively) (Figure 3A).
No CKIT+FC 3RIa+ cells were detected in the V fractions. In
further experiments we focused on the G2V hiPSC-1 line
(Figure 3B). After 10 days of differentiation and 4 days of
OP9 co-culture, 16.30% ± 4.82% CKIT+FC 3RIa+ cells were
detected in the cultures of V+ cells, whereas no to few
CKIT+FC 3RIa+ cells (0.42% ± 0.33%) were found in the
V cell cultures (n = 3; p = 0.030). Toluidine blue and rapid
Romanowsky staining of cells from G2V-hiPSC1 expanded
cultures confirmed mast cell morphology (Figure 3C).
Moreover, qRT-PCR verified increased expression of the
mature mast cell protease, TPSAB1 in differentiated G2V-
hiPSC1 as comparedwithundifferentiated cells (Figure 3D).
The consistency of the results from the G2V-hESC and
G2V-hiPSC clones indicate that our staged culture and
enrichment approach, although not as quantitatively
efficient as the G2V-mESC cultures, delivers a promising
platform for the generation of human mast cells within
12–16 days of culture initiation.DISCUSSION
The Gata2 reporter PSC approach represents a significant
advance in the rapid production of mast cells for research
(Table 1). Compared with previously published protocols
using limited sources of cells such as human blood (periph-1014 Stem Cell Reports j Vol. 11 j 1009–1020 j October 9, 2018eral, umbilical cord) and bone marrow, and unlimited PSC
sources, the staged G2V differentiation and enrichment
method shortens culture duration considerably (by
1 week for mouse and several weeks for human cultures).
This time-saving and resource-efficient method raises
prospects for production of mast cells (including patient-
specific) for high-throughput drug discovery and mecha-
nistic studies on mast cell-related disorders.
Gata2 Expression as a Reporter for Mast Cells
The Gata2 transcription factor is known to be expressed in
HSCs, HPCs, and mast cells (Jippo et al., 1996; Kaimakis
et al., 2016). As a nuclear factor it is not amenable to anti-
body-mediated viable cell enrichment by FACS sorting,
and the generation of reporters that accurately mimic
Gata2 without disrupting its expression levels or protein
function has been difficult (Minegishi et al., 2003). We
achieved faithful reporter gene expression by inserting an
IRESVenus sequence into the Gata2 30 UTR, thus precluding
disruption of the coding sequences or regulatory elements,
or functionalmodification (as in a fusion protein) ofGata2.
Such an approach allows for the parallel expression of the
Venus reporter together with the proper qualitative and
quantitative expression of Gata2 (Eich et al., 2018). Impor-
tantly, ourGata2 reporter approach has been verified in vivo
(Kaimakis et al., 2016) and shown to provide the appro-
priate physiologic levels of Gata2 expression for undis-
turbed hematopoietic development and differentiation.
VENUS protein levels correctly correspond to GATA2
protein levels (Eich et al., 2018), thus guaranteeing appro-
priate reporting of GATA2 expression in the in vitro G2V
ESC/iPSC models.
FACS analysis revealed varying levels of Venus expres-
sion in cells from G2V mESC differentiation cultures.
We have shown that a significant 3.5-fold increase in
Venus MFI between day 10 and day 14 of differentiation
(Figure 1I) corresponds to the appearance of mast cells,
thus supporting the view that the direct induction of
high GATA2 expression is a prerequisite for the rapid
commitment to the mast cell lineage (Sasaki et al., 2016)
and for the activation of mature mast cells (Masuda
et al., 2007).
G2VMast Cell Expansion Features
In addition to producing mast cells, we found that the
staged G2V mESC culture system produces self-renewing
mast cell progenitors. Replating experiments revealed large
increases in mast cell output over time. While it is known
that interleukin-3 (IL-3) and stem cell factor (SCF) lead to
increased mast cell output and function (Ito et al., 2012;
Lantz et al., 1998; Yamaguchi et al., 2013), our G2V
mESC produce these cells in 2–3 weeks, rather than the
4–12 weeks in other culture systems. Most similar to our
Figure 2. G2V ESC-Derived V+ Cells
Generate Mucosal and Connective Tissue-
Type Mast Cells that Express Proteases
and Degranulate
(A) Image showing the clonal expansion
capacity of a single V+ mast cell harvested
from stage 2 after 5 days. Area within the
dotted region shows part of such a colony
(>1,000 cells). Scale bar, 100 mm.
(B) Image of toluidine blue-stained mast
cells generated after stage 3 expansion.
Lighter blue indicates mucosal mast cells
(mMC) and darker blue connective tissue-
like mast cells (ctMC).
(C) Mast cell-specific gene expression in
undifferentiated ESCs (number of indepen-
dent experiments [n] = 3), day-10 V+ he-
matopoietic cells (stage 1, n = 3), expanded
mast cells (stage 3, n = 4) and mast cells
after clonal replating (rpMC, n = 3). RT,
reverse transcriptase; CPA, carboxypepti-
dase; mMCP, mouse mast cell protease.
(D) Image of toluidine blue-stained mast
cells generated after two serial clonal re-
platings of a single cell harvested from stage
2 co-culture. Scale bar, 100 mm.
(E) Quantitative gene expression analysis of
mast cell-specific genes in expanded G2V
mast cells. Expression levels were normal-
ized to 18S expression and compared with
the normalized levels in control mouse ear
tissue. Mean ± SEM, n = 3.
(F) ELISA assay showing the relative con-
centration of released tryptase in the me-
dium of c48/80-treated (5 mM) G2V mast cells compared with untreated cells. Tryptase levels were calculated based on a tryptase standard
curve. Level was set as 1 in untreated sample. *p < 0.05, n = 5.
(G) Immunoglobulin E (IgE) activation of degranulation. Functional assay showing the percentage of b-hexosaminidase release in the
supernatant of IgE activation/antigen stimulation-treated ESC-MCs and peritoneal MC (P-MC) compared with controls. b-Hexosaminidase
enzymatic activity was measured in supernatants and cell pellets and percent release was calculated as described in Experimental Pro-
cedures. Unpaired t test, two-tailed p value; n = 4.
Error bars represent means ± SEM.method, Yamaguchi et al. used co-cultures withOP9 cells to
achieve the production of 6.53 106mast cells from 13 105
mouse iPSCs in 4 weeks (Yamaguchi et al., 2013). From a
starting population of only 3 3 104 G2V mESCs, we have
achieved up to 3.8 3 106 mast cells within 3 weeks (or
12.65 3 106 mast cells from 1 3 105 G2V mESC), thus
demonstrating not only a more rapid production but a
more abundant production ofmast cells. Following stage 2,
on average every 1:2 to 1:6 Gata2+ cell was an MCp
and gave rise to a homogeneous colony containing more
than 500 mature mast cells. While the Gata2 reporter-
mediated enrichment focuses the co-culture system on
hematopoietic progenitors and MCp, we are currently at-
tempting to further shorten the culture period and mastcell output of mESC by other modifications to the culture
conditions.
GATA2 Reporter Can Be Exploited for Rapid Human
Mast Cell Generation
Our staged ESC culture takes advantage the Gata2 reporter
together with OP9 stromal cell co-culture for high-effi-
ciency mouse mast cell induction. Approximately 1%–2%
of cells after stage 1 culture are GATA2 expressing and the
OP9 co-culture step results in close to 100% differentiation
of GATA2-expressingmESC-derived cells tomast cells/mast
cell progenitors. We found this method to be applicable to
G2V human ESCs/iPSCs. Three independent lines of G2V
PSCs were cultured according to the multistep protocol,Stem Cell Reports j Vol. 11 j 1009–1020 j October 9, 2018 1015
Figure 3. Generation of Human GATA2VENUS Mast Cells
(A) The differentiation approach (Figure 1A) was applied to G2V-hESC/hiPSC to generate human mast cells. V+ cells were sorted from three
independent cell lines (day-7 G2V-hiPSC1, day-8 G2V-hiPSC2, and day-11 G2V-hESC differentiated EBs) and subjected to OP9 co-culture.
After 4 days (G2V-hiPSC1) or 5 days (G2V-hiPSC2, G2V-hESC) in step 2 culture, V+ and V cells were analyzed for mast cell markers CKIT and
FC 3RIa by FACS. Percentages of cells in gated regions are shown (n = 1 independent experiment for each cell line/time frame).
(B) Bar graph showing percentages (mean ± SEM) of CKIT+FC 3RIa+ cells obtained from the VENUS+ and VENUS fractions of cells harvested
from day-10 differentiated and 4-day co-cultured G2V-hiPSC1 cells (n = 3; p = 0.030).
(C) Image of toluidine blue (left) and rapid Romanowsky (right) stained mast cells generated after 5 days of step 3 expansion culture. Scale
bars, 50 mm (left) and 10 mm (right).
(D) Gene expression analysis of mast cell-specific protease tryptase (TPSAB1) in undifferentiated (n = 2) and differentiated G2V-hiPSC1
(n = 3) cells. GAPDH controlled for mRNA quantity. Relative expression levels were normalized to OP9 TPSAB1 expression, which was set as 1.except under serum-free conditions and with different
cytokines in step 1. In contrast tomouse cultures, high per-
centages (40%–70%) of GATA2-expressing cells were
observed after stage 1 (25- to 44-foldmore). Following stage
2 co-culture onOP9 cells, almost all mast cell/mast cell pro-
genitors were found in the GATA2+ fraction, as was found
for the mouse stage 2 cultures. However, the frequency
of human CKIT+FC 3R1a+ cells was many times lower.
Nonetheless, human mast cells can be obtained within
12–16 days of differentiation and Gata2 reporter would
enable the production of human mast cells that could be
enriched to high homogeneity, in contrast to mast cells
derived from wild-type non-reporter PSCs.
Our study highlights possible species-specific differences
betweenmPSCs andhPSCs and/or culture requirements for1016 Stem Cell Reports j Vol. 11 j 1009–1020 j October 9, 2018quantitatively efficient mast cell production. For example,
mESCs are thought to be naive whereas hESCs/hiPSCs are
primed and somewhat differentiated (Weinberger et al.,
2016). It will be interesting to test whether the efficiency
of hESC/hiPSC hematopoietic differentiation increases
in serum-containing cultures. Moreover, OP9 cells are
neonatal mouse bone marrow stromal cells that efficiently
support mouse hematopoietic cell development and differ-
entiation (Lynch et al., 2011). It would be beneficial to find
an equivalent human cell line for the co-culture step in the
hESC/hiPSC method And, by extension, examination of
which specific molecules produced by OP9 cells are
relevant to mast cell differentiation of mESCs would
allow for identification and testing of the relevant human
homologs. These and other approaches for increasing the
efficiency of human mast cell production are under inves-
tigation and will open up opportunities for the controlled
production of mast cells from patients suffering from
highly heterogeneous mast cell disorders such as mastocy-
tosis (Jawhar et al., 2017). CRISPR/Cas9 approaches facili-
tate the introduction of the Venus reporter gene into the
human GATA2 locus, as shown by our ability to generate
several G2V hESC and hiPSC lines that correctly report
HPCs and mast cells. Isogenic G2V hiPSC lines for mast
cell disorders can now be rapidly created by CRISPR/Cas9
engineering of gene mutations (CKIT D816V and/or
others) involved inmast cell diseases, such asmastocytosis.
The combination of these approaches for staged mast cell
differentiation promises to be useful for drug discovery
and testing in a disease-specific and patient-specific
manner, thus allowing for new treatment strategies and
better quality of life for those patients suffering from
mast cell-related conditions.EXPERIMENTAL PROCEDURES
Mouse and Human G2V PSCs
G2VmESCs were derived from the IB10 ESC line that is a subclone
of the E14 ESC line (from the 129/Ola mouse strain) and main-
tained along with IB10 wild-type control ESC as in Kaimakis
et al. (2016) and Kauts et al. (2016, 2018). H1 hESCs (WA01,
WiCell) and hiPSCs (Yang et al., 2017) (SFCi55, gift of L. Forrester
and CENSO Biotechnologies) were maintained on mouse embry-
onic fibroblasts, 0.1% gelatin-coated plates, in DMEM/F12+
knockout serum replacement (Thermo Fisher), GlutaMAX (Gibco),
minimum essential medium non-essential amino acids (Lonza),
50 mM b-mercaptoethanol (Gibco), and 10 mg/mL basic fibroblast
growth factor (bFGF) (PeproTech). Medium was replaced daily.
Mast Cell Generation Culture
The three-stage culture procedure is summarized in Figure 1A.
Stage 1. ESC Differentiation (Days 0–10)
G2VmESCs were trypsinized and feeder depleted by incubation in
Iscove’s modified Dulbecco’s medium (IMDM), 20% fetal bovine
serum (FBS) (HyClone), and 1% penicillin/streptomycin (P/S) for
30 min at 37C. For EB formation, G2V mESCs were aggregated
by culturing at 25,000 cells/mL in IMDM, 15% FBS, 2 mM
GlutaMAX (Gibco), 50 mg/mL ascorbic acid (Sigma), 4 3 104 M
monothioglycerol (Sigma), and 300 mg/mL transferrin (Roche) in
bacterial dishes. After 72 hr the medium was refreshed and
supplemented with 5% proteome free hybridoma medium
(Gibco). At day 6, medium was supplemented with murine SCF
(100 ng/mL), IL-3 (1 ng/mL), and IL-11 (5 ng/mL) (PeproTech)
and refreshed every other day. hPSC differentiation was as
described by Kennedy et al. (2012). In brief, hPSCs were cut using
StemPro EZPassage Tool (Thermo Fisher) and aggregates resus-
pended in StemPro-34 (Invitrogen), 10 ng/mL P/S, 2 mM L-gluta-
mine (Gibco), 1 mM ascorbic acid (Sigma-Aldrich), 4 3 104 M
monothioglycerol (Sigma-Aldrich), and 150 mg/mL transferrin
(Roche). Human bone morphogenetic protein 4 (10 ng/mL),bFGF (5 ng/mL), activin A, 6 mM SB-431542 (selective inhibitor
of the TGF-b type I receptor activin receptor-like kinase receptors),
vascular endothelial growth factor (15 ng/mL), Dickkopf-related
protein 1 (DKK, 150 ng/mL), IL-6 (10 ng/mL), insulin-like growth
factor 1 (25 ng/mL), IL-11 (5 ng/mL), SCF (50 ng/mL), erythropoi-
etin (EPO, 2 U/mL), thrombopoietin (TPO, 30 ng/mL), IL-3
(30 ng/mL), and Fms-related tyrosine kinase 3 ligand (FLT-3L,
10 ng/mL) (PeproTech) were added.
Stage 2. OP9 Co-culture for Hematopoietic/Mast Cell
Commitment (Days 10–14)
At day 10, EBs were washed in PBS, incubated with TrypLE Express
(Gibco) (37C, 3–5 min), and deactivated with PBS, 10% fetal calf
serum, an 1% P/S. Cells were suspended with a P1000 pipette. Ten
thousand V+ cells were sorted and plated on 30,000 OP9 cells pre-
seeded1 day earlier in 24-well plates in a-minimal essential
medium, 10% heat-inactivated FBS, 1% P/S, 20 ng/mL FLT-3L,
20 ng/mL IL-7 and/or 20 ng/mL IL-6, and 50 ng/mL SCF
(PeproTech). ForhPSCculture, the same concentration forhumancy-
tokines was used (PeproTech). V+ mast cells appeared after 2–4 days
and sorted cells used for experiments and further expansion.
Stage 3. Expansion
After 4 days of OP9 co-culture, V+ cells were sorted and plated
(500 cells/mL) inmethylcellulose (STEMCELLTechnologies). After
3–4 days, large dense colonies appeared. Colonies were counted af-
ter 3–7 days of culture, then cells were harvested by dissolving
methylcellulose in PBS and counted by trypan blue exclusion.
For replating, colonies were picked and single cells plated into
fresh methylcellulose.
Primary Hematopoietic Cell Cultures
Adult mice were sacrificed by cervical dislocation. Peritoneal cells
were obtained by lavage (PBS, 10% FBS, 1% P/S) as previously
described (Meurer et al., 2016) and bonemarrow cells by PBS-flush-
ing of the long bones. Cell suspensions were centrifuged for 5 min
at 1000 rpm at room temperature, resuspended in RPMI 1640
medium, 2 mM L-glutamine (Gibco), 15% heat-inactivated FBS
(Gibco), 1% P/S (Gibco), 0.07% b-mercaptoethanol (Gibco), and
10 mM HEPES (Sigma-Aldrich), and cultured (medium changes
every 3 days). For mast cell growth (2–3 weeks), 30 ng/mL IL-3
and 20 ng/mL SCF (Peprotech)were added and for basophil growth
(10 days), 10 ng/mL IL-3 was added. All mouse experimentation
was performed under the UK Animals Scientific Procedures Act
1986 Project License 70/8076 and performed in compliance with
Standards for Care and Use of Laboratory Animals.
Flow Cytometry
Venus expression was detected directly. Surface receptor
expression was analyzed using antibodies CD45-AF700 (1:400;
BioLegend, cat. #103127), CD19-PE (1:200; eBiosciences, cat.
#12–0193), GR1-APC-Cy7 (1:400; BD Biosciences, cat. # 557661),
CD11B-PerCP-Cy5.5 (1:500; eBioscience, cat. #45-0112-80),
TER119-BV421 (1:400; BD Horizon, cat. #563998), CKIT-
APCeFluor780 (1:800; eBioscience, cat. #47-1171-80), FC 3R1a-PE
(1:200, MAR-1; BioLegend, cat. #134308), CKIT-BV421 (1:200;
BDBiosciences, cat. #562609), andCD49B-APC (1:100; BioLegend,
cat. #108909) for murine cells and CD41-PE (1:50; BioLegend, cat.
#303705), FC 3RIa-PE (1:50; BioLegend, cat. #334610), andStem Cell Reports j Vol. 11 j 1009–1020 j October 9, 2018 1017
CKIT-PECy7 (1:50; BioLegend, cat. #313212) for human cells. Dead
cells were excluded with Hoechst 33342 (Life Technologies). Cells
were sorted/analyzed on FACSAria IISORP (BD Biosciences) with
FlowJo software (Tree Star).
Cytospin Staining
Fifteen thousand mouse mast cells (stage 3) were resuspended in
50 mL of PBS, transferred to sample chambers/glass slides, and
centrifuged (5 min, 200 rpm), methanol fixed (30 s), and toluidine
blue stained (Scientific Laboratory Supplies) (0.5 N HCl, 1 hr). Hu-
man cell cytospins were fixed in Carnoy’s fixative (60% absolute
alcohol [VWR Prolabo], 30% chloroform, 10% acetic acid [Sigma-
Aldrich], 1 hr), incubated in 70% ethanol, and stained in 0.1%
toluidine blue (0.5 N HCl, 45 min), then dried, dehydrated (95%
alcohol), andmountedwith Permafluor (Thermo Fisher Scientific).
Some human sample slides were stained with a Rapid Romanow-
sky Stain Pack kit (TCS Biosciences). An Axioskop2 (Zeiss) micro-
scope with 403 objective was used.
Mast Cell Activation/Degranulation Analyses
Mast cells (stage 3) (13 106) were resuspended in 1 mL of PBS and
stimulatedwith c48/80 (Sigma) (5 mg/mL, 60min, 5%CO2, 37
C).
After centrifugation, tryptase concentration in the supernatant
was quantified using a Mouse Mast Cell Tryptase (MCT) ELISA
Kit (Cusabio). A standard curve was generated using a four-param-
eter logistic (4-PL) curve fit. Mast cell degranulation (b-hexosa-
minidase release) was determined according to the protocol of
Kuehn et al. (2010). In brief, G2V-mESCS-MCs and control
PMCswere sensitized overnight with 1 mg/mLmouse anti-dinitro-
phenyl (DNP) IgE (Sigma-Aldrich). Following three washes with
HEPES buffer (pH 7.4), 50,000 cells/well were activated with
DNP-HSA (Sigma-Aldrich) and incubated in 37C for 60 min. Su-
pernatants were collected and cells lysed using 0.1% Triton X-100
in HEPES buffer. b-Hexosaminidase activity in supernatants
and cell lysates was measured using a colorimetric assay with
3.5 mg/mL p-nitrophenyl-N-acetyl-b-D-glucosamide (PNAG;
Sigma-Aldrich) as a substrate. After 90-min incubation at 37C,
the reaction was stopped with glycine buffer (400 mM, pH
10.7). The absorbance was measured at 405 nm (Varioskan Flash
microplate reader, Thermo Scientific). The percentage of b-hexos-
aminidase release was calculated according to the formula: %
b-hexosaminidase released = 1003 (supernatant content)/(super-
natant + lysate content).
Expression Analysis
Total RNA was extracted using an RNA mini or micro kit (Qiagen)
and standardized to 100 ng/mL. cDNA was synthesized using Su-
perscript VILO synthesis kit (Invitrogen) at 25C for 10 min,
42C for 60 min (primer extension), and 85C for 5 min (inactiva-
tion) in a Thermo Cycler (MJ Research PTC 200 BC-MJPC200). A
cDNA standard curve for qPCR primer efficiency validation was
made using an RNA dilution series (murine; HMC-1). Together
with standard curve R2 value, efficiency (E, %) of all the primer
sets was calculated by formula E = (10(1/slope)  1) 3 100 in 10-
and 2-fold dilutions. DDCt analysis was performed for primer sets
with an efficiency range of 95%–105% (all primers in this study).
TaqMan PCR was used for real-time RNA quantification. Primer1018 Stem Cell Reports j Vol. 11 j 1009–1020 j October 9, 2018sets were designed using the ‘‘Universal ProbeLibrary Assay
Design Center.’’ Semi-quantitative RT-PCR was performed using
BioMixRed (Bioline). For human Venus-sorted samples, total
RNAwas isolated and reverse transcribed using oligo-dT (Life Tech-
nologies) and SuperScript III (Life Technologies). qRT-PCR used
Fast SYBR Green Master Mix (Life Technologies). Primers are listed
in Table S1.Statistics
For two-group analysis, an unpaired two-tailed t test was used.
One-way ANOVA was used for multiple-group comparison, fol-
lowed by Kruskal-Wallis as a secondary test and Dunn’s multiple
comparisons test. Results are statistically significant at p < 0.05.
Data are shown asmean ± SEM, n = number of independent exper-
iments. Data analysis was done using GraphPad Prism (GraphPad
Software).
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